Compare AstraZeneca plc (AZN) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs VanEck Vietnam ETF — how do they compare? AstraZeneca plc trades at $166.95 (market cap $253.13B), while VanEck Vietnam ETF trades at $17.45. The key difference: AstraZeneca plc pays a 1.92% dividend while VanEck Vietnam ETF pays none. Which is the better fit depends on your goals.
| AZN | VNM | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $19.80 |
52-Week Low | $137.44 | $15.04 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
VNM trades at $17.53, down 2.5% today, with a bearish technical outlook as moving averages signal strong selling pressure. The stock's key financial ratios are currently unavailable, limiting fundamental assessment. Recent news highlights Vietnam ETF underperformance and regional economic pressures, including power grid strain from heatwaves and geopolitical tensions affecting emerging markets.
The outlook remains cautious due to technical weakness and emerging market headwinds. Investment opportunities hinge on Vietnam's economic recovery and foreign institutional flows post-FTSE Russell reclassification, but risks include persistent underperformance versus global equities and domestic infrastructure challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
